Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone; Tretinoin
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 18 Dec 2013 Planned end date changed from 1 Feb 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top